---
document_datetime: 2025-08-05 15:57:45
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rixathon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rixathon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8657976
conversion_datetime: 2025-12-26 11:59:28.687061
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rixathon

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                             |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------|
| Variation type IB /  | This was an application for a variation | 10/07/2025                          |                                             | Annex II                         | To align the RMP with that of the reference product |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000249103                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted To align the RMP with that of the reference product by updating the ATC code, removing the important identified risks `Hepatitis B (HBV) reactivation (all indications)', `Hypogammaglobulinemia (non-oncology indications)', 'administration route error (NHL/CLL)' and missing information `Long- term use in Granulomatosis with polyangiitis (GPA)/ microscopic polyangiitis (MPA) patients (GPA/MPA)' `Relapses' (for GPA/MPA) from the list of safety concerns. To remove the targeted follow-up questionnaire (TFUQ) details and the additional risk minimization measures HCP educational leaflet and Patient educational   |            | by updating the ATC code, removing the important identified risks `Hepatitis B (HBV) reactivation (all indications)', `Hypogammaglobulinemia (non- oncology indications)', 'administration route error (NHL/CLL)' and missing information `Long-term use in Granulomatosis with polyangiitis (GPA)/ microscopic polyangiitis (MPA) patients (GPA/MPA)' `Relapses' (for GPA/MPA) from the list of safety concerns. To remove the targeted follow-up questionnaire (TFUQ) details and the additional risk minimization measures HCP educational leaflet and Patient educational leaflet, Annex IID is updated accordingly.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000254599 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 26/06/2025 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                                       | B.II.g) Design Space and post approval change management protocol - B.II.g.2 Introduction of a post approval change management protocol related to the finished product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |                                  |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|
| Variation type IB / EMA/VR/0000261990 | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - to update sections 4.1, 4.2, 4.3, 4.4, 4.8, 5.1, 6.2, 6.4 and 6.5 of the SmPC, Annex II, Labelling and Package Leaflet, following assessment of the same changes for the reference product MabThera (EMEA/H/C/000165/II/0201/G). In addition, the MAH introduced the polysorbate content warning in section 2 and 4.4 of the SmPC as well as in section 2 of the Package Leaflet in | 15/05/2025 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                                       | the guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (as per Amendment from 17 Apr 2024). Moreover, the list of local representatives in section 6 of the Package Leaflet with changes of contact details for the following countries: Luxembourg, Czech Republic, Denmark/Norway/Island/Sweden, Italy, Cyprus and the deletion of United Kingdom (NI) according to the QRD template 10.4.   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000261094 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted                                                                                                                                    | 08/05/2025 | N/A |
| Variation type IB / EMA/VR/0000249064 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer                                                                                                                           | 03/04/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                          | (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted   |            |     |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA_IN / EMA/VR/0000243018 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.a Implementation of wording agreed by the competent authority - Refused                                                                                                                  | 05/02/2025 | N/A |